- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.09. | NewcelX Ltd.: NewCelX Management to Attend Breakthrough T1D Congress in Philadelphia, Advancing Its Mission to Develop a Cure for Type 1 Diabetes | 1 | GlobeNewswire (USA) | ||
| 18.09. | NLS Pharmaceutics GAAP EPS of -$0.96 | 1 | Seeking Alpha | ||
| 18.09. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 31.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 4 | SEC Filings | ||
| 31.07. | NewcelX Ltd.: NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing | 1 | GlobeNewswire (USA) | ||
| NEWCELX Aktie jetzt für 0€ handeln | |||||
| 15.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 13.07. | Laidlaw initiates NewcelX stock with buy rating on diabetes therapy | 1 | Investing.com | ||
| 08.07. | NewcelX beruft Diabetes-Forscher Ricordi in den wissenschaftlichen Beirat | 1 | Investing.com Deutsch | ||
| 08.07. | NewcelX appoints diabetes researcher Ricordi to advisory board | 1 | Investing.com | ||
| 08.07. | NewcelX Ltd.: NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board | 2 | GlobeNewswire (USA) | ||
| 08.07. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 01.07. | NewcelX Ltd.: NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes | 442 | GlobeNewswire (Europe) | ZURICH, July 01, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq: NCEL), a clinical-stage regenerative medicine company developing stem-cell-derived therapies, announced the successful completion... ► Artikel lesen | |
| 30.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 15.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 05.06. | NewcelX Ltd. - 6-K, Report of foreign issuer | 1 | SEC Filings | ||
| 27.05. | NewcelX Ltd. - 6-K, Report of foreign issuer | 2 | SEC Filings | ||
| 27.05. | NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes | 689 | GlobeNewswire (Europe) | Pre-IND meeting has been scheduled with FDA to advance type 1 diabetes treatment to First-In-Human clinical trial ZURICH, Switzerland, May 27, 2026 (GLOBE NEWSWIRE) -- NewcelX Ltd. ("NewcelX"; Nasdaq:... ► Artikel lesen | |
| 27.05. | EXCLUSIVE: NewcelX Advances Diabetes Therapy Toward Human Trials With FDA Pre-IND Submission | 2 | Benzinga.com | ||
| 06.05. | NewcelX akquiriert bis zu 3,4 Millionen Dollar | 1 | punkt4.info | ||
| 01.05. | NLS Pharmaceutics GAAP EPS of -$2.16 | 1 | Seeking Alpha |
1 2 Weiter >>
37 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIOFRONTERA | 3,370 | -0,30 % | PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG | DJ PTA-AFR: Biofrontera AG: Vorabbekanntmachung über die Veröffentlichung von Finanzberichten gemäß §§ 114-117 WpHG
Vorabbekanntmachung Finanzberichte gemäß ---- 114-117 WpHG
Biofrontera... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,275 | +5,36 % | Defence Therapeutics Inc.: Defence Therapeutics to Take the Stage at World ADC San Diego to Discuss the Next Frontier in Antibody-Drug Conjugates | Montreal, Quebec--(Newsfile Corp. - October 1, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology company developing... ► Artikel lesen | |
| TRAWS PHARMA | 0,542 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -4- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameUS1509643029 CENNTRO... ► Artikel lesen | |
| CURIS | 0,797 | +13,95 % | Curis, Inc. Announces Pricing of $5.6 Million Public Offering | LEXINGTON, Mass., Aug. 13, 2026 /PRNewswire/ -- Curis, Inc. (Nasdaq: CRIS), a biotechnology company focused on the development of emavusertib (CA-4948), an orally... ► Artikel lesen | |
| GENPREX | 2,715 | -0,18 % | Genprex, Inc.: Genprex Selects Leading Clinical and Commercial Contract Development and Manufacturing Organization for Manufacturing Scale Up of Diabetes Gene Therapy | Collaboration Allows Genprex to Accelerate Manufacturing Processes for IND-Enabling Preclinical Studies and Future Clinical Trials
AUSTIN, Texas, Aug. 18, 2026... ► Artikel lesen | |
| TVARDI THERAPEUTICS | 0,870 | -6,45 % | Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update | Reported topline healthy volunteer results for next-generation STAT3 inhibitor TTI-109, confirming the prodrug design, improved tolerability and reductions in disease-relevant immune cell populations... ► Artikel lesen | |
| NEOVACS | 0,185 | +62,28 % | XFRA NEW INSTRUMENTS AVAILABLE ON 23.06.2026 | The following instruments on XETRA do have their first trading 23.06.2026 Die folgenden Instrumente in XETRA haben ihren ersten Handelstag 23.06.2026
Aktien
1 CNE100007CW0 Shenzen Xunce Technology... ► Artikel lesen | |
| ALAUNOS THERAPEUTICS | 0,795 | 0,00 % | Alaunos Therapeutics, Inc.: Alaunos Reports New Preclinical ALN1003 Data Showing Lower Liver Weight After Adjustment for Body Fat Percentage in 48-Day DIO Mouse Study | This statistical finding supports a lower liver-weight signal after adjustment for body fat percentage, suggesting the finding was not fully explained by measured body fat in this modelLiver-weight... ► Artikel lesen | |
| MARKER THERAPEUTICS | 0,795 | +0,63 % | H.C. Wainwright reiterates Marker Therapeutics stock rating at buy | ||
| AINOS | 1,350 | +1,50 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 02.10.2026 -3- | The following instruments on Boerse Frankfurt do have their last trading day on 02.10.2026Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 02.10.2026ISIN NameKYG200801002 CBAK... ► Artikel lesen | |
| MATINAS BIOPHARMA | 2,810 | 0,00 % | XFRA 6LJ: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILMATINA.BIOPHA. O.N.... ► Artikel lesen | |
| ENVERIC BIOSCIENCES | 1,510 | 0,00 % | Enveric receives U.S. patent allowance for psychiatric compounds | ||
| NEUPHORIA THERAPEUTICS | 3,450 | 0,00 % | Neuphoria Therapeutics, Inc.: Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | Neuphoria Therapeutics confirms it is in talks with Scancell Holdings plc about a possible combination BURLINGTON, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Neuphoria Therapeutics Inc. ("Neuphoria"... ► Artikel lesen | |
| SCINAI IMMUNOTHERAPEUTICS LTD | 1,270 | +0,79 % | SCINAI IMMUNOTHERAPEUTICS LTD: Scinai Regains Compliance with Nasdaq Minimum Bid Price Requirement | Nasdaq confirms compliance with Listing Rule 5550(a)(2) after 19 consecutive business days with a closing bid price at or above $1.00; minimum bid price matter... ► Artikel lesen | |
| CLEARMIND MEDICINE | 6,000 | 0,00 % | XFRA ISIN CHANGE | Einstellung Aufnahme ISIN Name Einstellung mit Ablauf: ISIN Name Ab dem: AnmerkungenSE0018538068 Verve Group Media SE 02.10.2026 IE000ZVY0237 Verve Group Media SE 05.10.2026 Tausch 1:1 CA86332K4000 Strikepoint... ► Artikel lesen |
NEWCELX LTD gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von 0,000 (0,00 %) liegt der Kurs bei 2,980 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu NEWCELX LTD finden Sie auf Wallstreet Online.